EPFL BioE Talks SERIES "How Human Cells Deal With Genome Editing Tools"
Event details
| Date | 03.05.2021 |
| Hour | 16:00 › 17:00 |
| Speaker | Prof. Jacob Corn, ETH Zurich (CH) |
| Location | Online |
| Category | Conferences - Seminars |
WEEKLY EPFL BIOE TALKS SERIES
Abstract:
Genome manipulation with CRISPR-Cas systems has rapidly expanded in scope to include a dizzying array of Cas enzymes and engineered tools. The success of these systems completely depends upon cellular pathways that turn Cas-targeted insults into desired genomic outcomes. Our surprisingly poor understanding of the mechanisms underlying genome editing necessitates extensive trial-and-error, generally starting from scratch in each new cellular and organismal context. The Corn lab studies how cells deal with genome editing tools, with an eye towards hypothesis-driven design of personalized therapies.
Bio:
Jacob Corn is the Professor of Genome Biology at the ETH Zurich. His research aims to better understand and treat disease through next-generation genome editing technologies. Jacob’s career has bridged academia and industry, working in therapeutic areas that include infectious disease, neurobiology, and oncology. His research takes a multidisciplinary approach, combining cellular biochemistry, functional genomics, computational biology, bioengineering, and biophysics. Jacob’s graduate studies at the University of California, Berkeley with James Berger explored how cells replicate their genomes, and was recognized with several honors, including the Nicholas Cozzarelli and Harold Weintraub awards. Jacob’s work as a Jane Coffin Childs postdoctoral fellow at the University of Washington created the world’s first computationally designed de novo protein interaction and a protein-based inhibitor to treat flu. Jacob began his independent research career as a group leader at Genentech, where his lab discovered biological mechanisms for challenging therapeutic targets. Jacob then moved back to academia as the founding Scientific Director of the Innovative Genomics Institute and faculty at UC Berkeley. His lab’s current focus is the development of genome editing, the mechanisms by which cells repair their DNA, and the maintenance of healthy organelles. In his spare time, Jacob enjoys trips in the mountains and rock climbing.
Zoom link (with registration) for attending remotely: https://go.epfl.ch/EPFLBioETalks
IMPORTANT NOTICE: due to restrictions resulting from the ongoing Covid-19 pandemic, this seminar can be followed via Zoom web-streaming only, (following prior one-time registration through the link above).
Abstract:
Genome manipulation with CRISPR-Cas systems has rapidly expanded in scope to include a dizzying array of Cas enzymes and engineered tools. The success of these systems completely depends upon cellular pathways that turn Cas-targeted insults into desired genomic outcomes. Our surprisingly poor understanding of the mechanisms underlying genome editing necessitates extensive trial-and-error, generally starting from scratch in each new cellular and organismal context. The Corn lab studies how cells deal with genome editing tools, with an eye towards hypothesis-driven design of personalized therapies.
Bio:
Jacob Corn is the Professor of Genome Biology at the ETH Zurich. His research aims to better understand and treat disease through next-generation genome editing technologies. Jacob’s career has bridged academia and industry, working in therapeutic areas that include infectious disease, neurobiology, and oncology. His research takes a multidisciplinary approach, combining cellular biochemistry, functional genomics, computational biology, bioengineering, and biophysics. Jacob’s graduate studies at the University of California, Berkeley with James Berger explored how cells replicate their genomes, and was recognized with several honors, including the Nicholas Cozzarelli and Harold Weintraub awards. Jacob’s work as a Jane Coffin Childs postdoctoral fellow at the University of Washington created the world’s first computationally designed de novo protein interaction and a protein-based inhibitor to treat flu. Jacob began his independent research career as a group leader at Genentech, where his lab discovered biological mechanisms for challenging therapeutic targets. Jacob then moved back to academia as the founding Scientific Director of the Innovative Genomics Institute and faculty at UC Berkeley. His lab’s current focus is the development of genome editing, the mechanisms by which cells repair their DNA, and the maintenance of healthy organelles. In his spare time, Jacob enjoys trips in the mountains and rock climbing.
Zoom link (with registration) for attending remotely: https://go.epfl.ch/EPFLBioETalks
IMPORTANT NOTICE: due to restrictions resulting from the ongoing Covid-19 pandemic, this seminar can be followed via Zoom web-streaming only, (following prior one-time registration through the link above).
Practical information
- Informed public
- Registration required
Organizer
- Prof. Patrick Barth, EPFL
Contact
- Institute of Bioengineering (IBI), Dietrich REINHARD